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Abstract
Background: Randomized controlled trials are the gold-standard for clinical trials. However, randomization is not
always feasible. In this article we propose a prospective and adaptive matched case-control trial design assuming that
a control group already exists.
Methods: We propose and discuss an interim analysis step to estimate the matching rate using a resampling step
followed by a sample size recalculation. The sample size recalculation is based on the observed mean resampling
matching rate. We applied our approach in a simulation study and to a real data set to evaluate the characteristics of
the proposed design and to compare the results to a naive approach.
Results: The proposed design achieves at least 10% higher matching rate than the naive approach at final analysis,
thus providing a better estimation of the true matching rate. A good choice for the interim analysis seems to be a
fraction of around 12 to
2
3 of the control patients.
Conclusion: The proposed resampling step in a prospective matched case-control trial design leads to an improved
estimate of the final matching rate and, thus, to a gain in power of the approach due to sensible sample size
recalculation.
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Background
Randomized controlled designs are the gold-standard for
clinical trials. The advantage of a random allocation of
patients to treatment and control group is the comparabil-
ity of patient groups. However, there are situations where
a randomized trial is not applicable, for instance, due
to ethical concerns or practical reasons, but an observa-
tional trial is possible [1, 2]. An observational single-arm
study might be an option, but has the disadvantage that
a direct comparison to placebo or the standard ther-
apy is not possible. When data on the control recruited
within an earlier study is available, an alternative way
would be to use this external control group for compari-
son. Naively comparing study arms of different trials may
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lead to severe bias due to differences in patient charac-
teristics. The lack of comparability can be addressed by
matching procedures as, for example, Optimal Matching
or Propensity Score Matching [3, 4]. These methods aim
to balance the groups by the variables considered within
the matching procedure. Combining a prospective single-
arm study with an external control group under the usage
of a matching approach is called a prospective matched
case-control trial [5].
One essential part in planning a clinical trial is the
calculation of the required sample size. In a prospective
matched case-control trial, sample size calculation is not
straightforward. The aim is to find an appropriate match-
ing partner for as many patients of the already recruited
study arm as possible. Usually it cannot be expected to
find a matching partner for all patients in the control
group when recruiting just the same number of patients
in the treatment arm. Therefore, published trials fixed an
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additional percentage of intervention patients; for exam-
ple, the trial of Charpentier et al. [5] recruited 1.3 times
the number of control patients. In case a lower or higher
number of patients can be matched to one of the controls
than expected, the sample size would be too small or more
patients than needed are recruited. In the following, the
fraction of patientsmatched to one of the controls is called
matching rate.
This work is motivated by a real data example, the
KEEP SIMPLEST trial [6]. The trial aimed to com-
pare aspects of periinterventional management in acute
ischemic stroke (AIS) patients treated according to a new
SOP (standard operating procedure) with patients hav-
ing been randomized into the conscious sedation group
of the SIESTA trial [7]. A randomized controlled trial
was not applicable, because the early stage application
of the new method cannot be reproduced. Therefore, a
prospective matched case-control design was planned.
The matching rate was unknown and as in most other
trials most likely less than 100%, meaning that recruit-
ing just the same number of patients as in the external
control arm will not result in a situation where a match-
ing partner is found for all patients in the control group.
A possibility to address this uncertainty concerning the
matching rate could be to perform an interim analysis
to estimate the actual matching rate. The results of the
interim analysis are then used to recalculate the sam-
ple size. This leads to an adaptive matched case-control
design.
The recalculation might be done by using all avail-
able patients in the matching procedure (at interim and
final analysis, respectively). Based on the matching rate
observed in the interim analysis, the sample size is recal-
culated. This strategy will be called the naive method. In
practice, we expect there may occur a potential overes-
timation of the matching rate. In consequence, a smaller
number of patients than necessary is recruited after
interim analysis and therefore, a smaller matching rate
is achieved at the final analysis. To avoid overestimation,
we propose a method for calculating the matching rate at
interim analysis which is characterized by a resampling
step and recalculation of the sample size based on the
mean resampling matching rate. The time point of this
interim analysis needs to be fixed at the beginning of the
trial. We conducted a simulation study to investigate the
operational characteristics of the proposed approach and
to develop a recommendation for the time point of interim
analysis.
In “Methods”, we explain the proposed method for cal-
culating the sample size and the details of the conducted
simulation study. Its results are described and followed
by the application to the real data example in “Results”.
The results are discussed and conclusions are drawn in
“Discussion and conclusion ’’.
Methods
We propose an adaptive design for recalculating the sam-
ple size in a prospective matched case-control trial which
is characterized by a resampling approach and a propen-
sity score matching step.
Within the suggested design, two matching steps are
conducted. At interim analysis, the matching rate is deter-
mined and is used for recalculation of the sample size
needed to find a matching partner to all control patients
in the final analysis. The matching procedure at interim
analysis is solely used for calculating the matching rate;
the final 1:1 matches are determined in the final analysis.
To find pairs of treated and control patients, the propen-
sity score method by Rosenbaum and Rubin [8, 9] is used.
Propensity score matching aims to minimize the influ-
ence of observed and considered baseline characteristics
on the treatment effect [10]. The propensity score e(X) is
the conditional probability of being assigned to the treated
study arm given (relevant) confounders X [10]. Assuming
that there are n patients included, the propensity score is
defined as
e(Xi) = P(Zi = 1 | Xi) i = 1, . . . , n,
where Zi ∈ {0, 1} defines the group assignment and Xi is
the vector of considered baseline characteristics.
The propensity score is estimated by using baseline
characteristics as covariates in a logistic regression model
with treatment status as outcome variable [9]
logit(Zi) = β0,gr + β1,grXi1 + β2,grXi2 + . . . (1)
Thismodel provides the propensity scores, the probabil-
ity to be assigned to the treatment group. The treatment
and control patients are matched according to the logit of
the estimated propensity score
ln e(Xi)1 − e(Xi)
by using some caliper width of these estimates [4].
Austin recommend a caliper width of 0.2 of the standard
deviation of the logit of the propensity score [10].
The already recruited study arm includes ncontrol
patients. To determine the matching rate at the interim
analysis, we resample the control patients. In order to
further avoid an overestimation of the matching rate at
interim analysis equally sized groups are used for the
matching procedure at interim analysis. That means, a
sample of ntreated,interim is taken from the ncontrol patients
without replacement. Using the sampled set of patients,
the matching step is performed which is explained in
the following. This resampling and the matching step at
interim analysis are repeated b times.
We calculate themean resamplingmatching ratemr and
the lower limit of the 100 · (1−αCI) % confidence interval
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(CI) (using ncontrol)
lmr = mr − φ(1 − αCI) ·
√
mr ∗ (1 − mr)/ncontrol. (2)
The total number of patients needed in the treated
group is estimated by
ntreated,final = ncontrollmr . (3)
In the following, this approach is called resampling CI
method.
Another option would be to use a quantile of the distri-
bution of the resampling matching rates which are inde-
pendent of the number of patients in the control group.
One would expect to observe a highermatching rate in tri-
als with a large control arm, because a higher diversity of
patients may be represented. Therefore, taking the num-
ber of control patients into account has the advantage of
a smaller confidence interval for a larger number of con-
trol patients. For this reason, we stick with our proposed
definition of the 100 · (1 − αCI)% CI.
Steps of the procedure at interim analysis:
Given entities:
• b the number of resampling steps.
• ncontrol the number of control patients in already
recruited study arm.
• ntreated,interim the number of treated patients at
interim analysis.
Step 1 Repeat (a) - (d) b times:
(a) Sample ntreated,interim patients without
replacement out of the control group.
(b) Calculate propensity scores for sampled
control patients and treated patients.
(c) Conduct a 1:1 matching according to the
logit of the propensity scores.
(d) Calculate the matching rate mr.
Step 2 Calculate the mean matching ratemr of the b
matching rates calculated in step 1.
Step 3 Calculate the lower limit of the 100 · (1 − αCI)%
confidence interval using formula (2).
Step 4 Calculate the total number of treated patients
needed for analysis as in formula (3).
We conducted a simulation study with 10,000 replica-
tions of each scenario, to assess the performance of our
approach. First, we compare the resampling CI method
for recalculating the sample size to the naive strategy. The
second part covers the determination of the optimal time
point for the interim analysis.
Table 1 Distributions and regression models used for simulating
the data
Variable Group Distribution Model
X1 both Bin(1; 0.5)
X2 both Bin(1; 0.2)




1 − P(Z = 1)
)
= −0.6 + 0.35X1 − 0.01X3
X4 control Bin(10; 0.8)
X4 treated Bin(10; 0.75)
X5 control N(17; 5)
X5 treated N(16; 4)




1 − P(Y = 1)
)
= −0.5 + Z + 0.2X4
Simulation setting
General setting
The chosen values for the involved parameters are
simulated inspired by the clinical example (“Real data
example” section). Some simplifications (e.g. less vari-
ables within the matching procedure) were made for the
simulation study.
The outcome variable is assumed to be binary indicating
some favourable event and the corresponding hypotheses
are
H0 : pcontrol ≥ ptreated
H1 : pcontrol < ptreated,
where pcontrol and ptreated are the true rates in the control
and the treatment group, respectively.
All distribution parameters and regression coefficients
used to simulate the data are given in Table 1. The simu-
lated data includes three binary variables (incl. the group
variable Z), one categorical variable, and two continuous
variables. The variables are used to simulate the group
assignment and the outcome variable, as well as they are
considered within the matching procedure.
First, two binary (X1,X2) and one continuous variable
(X3) are sampled which describe for example gender, dia-
betes (yes/no), and age.
The group assignment depends on the variables X1 and
X3. Therefore, in the next step, the group variable is sim-
ulated based on a logistic regression model using the
baseline variables X1 and X3.
Based on the group allocation (group is considered
as Z in the following), two additional variables (X4 and
X5) are simulated. The variable X4 is an ordinal variable
with 10 levels which represent the ASPECTS score here.
The Alberta Stroke Program Early CT score (ASPECTS)
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is a tool for detecting early ischemic changes on non-
contrast CT scans [11]. The variable X5 follows a normal
distribution and describes here the NIHSS. The National
Institutes of Health Stroke Scale (NIHSS) is a tool to
assess stroke severity [12]. These two additional variables
are sampled out of different distributions (according to
the group). By using a logistic regression model for the
group allocation, as given in Table 1 for variable Z, and
sampling clinical variables out of different distributions,
differences between the groups are simulated which can
be addressed by the matching procedure. In order to
simplify the simulation study, the variables X1 to X5 are
assumed to be independent. However, in practice correla-
tionsmay occure and should be considered when selecting
the matching variables.
The propensity score is estimated by using the base-
line variables X2, X3, and X5 as covariates in a logistic
regressionmodel with group as outcome variable (Z). This
model includes baseline variable X2 which is not part of
the true group model. This leads to a misspecification of
the propensity score model. However, the true model is
usually not known and therefore this setting avoids to be
overoptimistic in the simulations.
The confidence level is set to αCI ∈ {0.01, 0.05, 0.1},
and hence the resampling CI method is evaluated for
99%, 95%, and 90% confidence intervals in this simulation
study.
For testing the null-hypothesis at the end of the trial, the
McNemar test for paired data is used to account for the
matched design.
Fixed time point - varying number of control patients
We start with a given number of patients in the control
group ncontrol and a fixed fraction t of patients for the
interim analysis. We set t = 0.5 and
ncontrol ∈{25, 50, 75, 100, 125, 150, 175, 200,
225, 250, 275, 300}.
The number of patients needed to show the simulated
effect with a power of 80% at a type I error rate of 5%
would have been 142 per group. We investigate under-
powered as well as overpowered scenarios. Underpow-
ered situtations occure when the expected effect in the
existing trial, where our control group is taken from, was
higher than expected in the new trial. In cases with a
smaller expected effect or multiple primary hypothesis in
the existing trial we may face an overpowered scenario.
At interim analysis, we calculated the matching rate on
b = 200 resampling sets of size ntreated,interim. Using the
simulated data as described above and performing the
steps listed above, we compare the proposed method with
the naive approach. For evaluating the properties of the
two approaches, the matching rate at final analysis, the
recruited sample size ntreated,final, as well as the type I error
and power at final analysis were evaluated.
Time point of interim analysis
The starting point is a fixed number of patients (in the
control group) ncontrol used as one arm of our controlled
trial. The confidence level for the resampling CI method
is set to 99%, αCI = 0.01 respectively. The “time points” s




















For recalculation of the sample size, the resampling CI
method as well as the naive approach is used. Our recom-
mendation will be based on the evaluation of thematching
rate, the recruited sample size ntreated, as well as the type I
error and power at final analysis.
We considered a small (ncontrol = 50), medium
(ncontrol = 150), and a large (ncontrol = 500) sam-
ple size in the control group to identify the influence
on the time point of interim analysis. The regres-
sion coefficient βZ,outcome varies between the consid-
ered sample sizes to obtain 80% power within each
scenario:
small: βZ,outcome = 2
medium: βZ,outcome = 1
large: βZ,outcome = 0.55
For the small sample size, the considered time points of
interim analysis start at 13 · ncontrol and for the medium
sample size at 14 · ncontrol; this is due to problems in
finding matching partners if fewer than 15 patients are
included in thematching procedure at the interim analysis
step.
All simulations were done in R version 3.4.3 with the
packages Matching (using the function Match) and boot
(using the function inv.logit) [13–15].
Results
Simulation results
First, the results using a fixed time point but varying the
number of control patients are shown and discussed, fol-
lowed by the results for the time point of interim analysis
which is assessed for both described methods.
Fixed time point - varying number of control patients
Comparing the matching rate curves at interim and final
analysis within the naive approach, one observes that the
matching rate at interim analysis is higher in all scenarios.
The consequence of an overestimation of the matching
rate at interim analysis is the recruitment of a too small
number of patients. If the matching rate is smaller at
final analysis (overestimation of matching rate at interim
analysis), this results in a loss of power (Figs. 1, 2).
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Fig. 1Mean matching rate for different sample sizes in control group. Time point of interim analysis is 12 · ncontrol
Our proposed method uses equal sample sizes for
the matching procedure at interim analysis which
underestimates the true matching rate. Therefore, more
patients are recruited (Fig. 3) and a higher matching rate
is achieved at the final analysis. Hence, too much matched
pairs are included in the final analysis which results in a
higher power.
For the naive method, we observed a dependency
between the matching rate and the number of patients in
the control group: the matching rate grows with the num-
ber of patients in the control group. In contrast, for our
proposed method the matching rate at final analysis stays
on a constant level with a mean matching rate between
91.7 - 91.8% for αCI = 0.01
Here, the required number of patients per group in a
fixed design would have been n = 142. For the proposed
design, 80% power is reached for ncontrol ≈ 150. Thus,
a power of 80% is achieved requiring only slightly more
patients in the control group than would have been in a
fixed randomized design (Fig. 2). This higher number of
control patients is caused by the matching rate which is
lower than 100% (Fig. 1).
Type I error rate is approximately 5% (between 4.37%
and 5.72%) for all scenarios and both methods. As
Fig. 2 Power for different sample sizes in control group. Time point of interim analysis is 12 · ncontrol
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Fig. 3Mean sample size in treated group for different sample sizes in control group. Time point of interim analysis is 12 · ncontrol
expected, a difference between the two methods accord-
ing to the type 1 error is not observed (Fig. 4).
Varying the confidence level within the resampling CI
method results in small differences in the mean lower CI
limit of the matching rate. The mean lower CI limit of
the matching rate at interim analysis increases slightly for
increasing αCI or decreasing confidence level, respectively
(Table 2). This increase leads to a slightly lower num-
ber of recruited patients for lower confidence levels. For
αCI = 0.05, the mean recruited sample size in the treat-
ment group is around 4 patients higher than for αCI = 0.1,
and for αCI = 0.01 is for another 8 patients higher, for
details see Table 3.
Time point of interim analysis
In this section, we only consider the results for a medium
sample size in the control arm (ncontrol = 150), as the
simulations for small and large sample sizes show compa-
rable results.
Using the naive method, we observe for early time
points of the interim analysis a matching rate close to
100%, but in the final analysis, it is less than 85% (Fig. 5).
Fig. 4 Type I error rate for different sample sizes in control group. Time point of interim analysis is 12 · ncontrol
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Table 2 Mean matching rate/mean lower CI limit of the
matching rate at interim and final analysis for the naive approach
and the resampling CI method for different numbers of patients
in the control group
Interim Final Interim Final
ncontrol Naiv 99%-CI
50 0.89 0.79 0.49 0.92
75 0.93 0.81 0.58 0.92
100 0.95 0.82 0.64 0.92
125 0.96 0.83 0.67 0.92
150 0.97 0.84 0.70 0.92
175 0.98 0.84 0.72 0.92
200 0.98 0.84 0.73 0.92
225 0.98 0.85 0.74 0.92
250 0.99 0.85 0.76 0.92
275 0.99 0.85 0.76 0.92
300 0.99 0.86 0.77 0.92
95%-CI 90%-CI
50 0.54 0.91 0.56 0.90
75 0.62 0.91 0.64 0.90
100 0.67 0.91 0.68 0.91
125 0.70 0.91 0.71 0.91
150 0.72 0.91 0.73 0.91
175 0.74 0.91 0.75 0.91
200 0.75 0.91 0.76 0.91
225 0.76 0.91 0.77 0.91
250 0.77 0.91 0.78 0.91
275 0.78 0.91 0.79 0.91
300 0.79 0.91 0.80 0.91
The resampling CI method is applied for different confidence levels
(αCI ∈ {0.01, 0.05, 0.1})
Even for later time points, the matching rate is lower than
90% and as a consequence the power is less than 80% for
all considered time points (Fig. 6). The total sample size is
lowest for the early time point (Fig. 7) because the match-
ing rate at interim analysis is highest for this time point.
As expected, the type 1 error rate is around 5% (Fig. 8).
Our proposed method uses equal sized groups at the
interim analysis. When performing an early interim anal-
ysis, the matching rate is very low and a high number
of patients need to be additionally recruited for the final
analysis. Comparing the matching rate at the final analysis
between the different time points, the gain in the match-
ing rate and therefore in power is small when performing
an early interim analysis. With an increasing number of
patients at interim analysis the matching rate seems to
converge and the changes are very small (in the match-
ing rate) when increasing the number of patients in the
Table 3 Mean total number of recruited patients in the treament
group for the naive approach and the resampling CI method for
different numbers of patients in the control group
ncontrol Naiv 99%-CI 95%-CI 90%-CI
50 57.20 103.05 94.11 89.97
75 81.88 130.51 122.83 119.10
100 106.24 158.13 150.99 147.45
125 130.73 187.46 180.42 176.88
150 155.34 215.80 208.85 205.32
175 179.98 245.10 238.09 234.52
200 204.84 273.86 266.81 263.19
225 229.42 303.28 296.11 292.42
250 254.39 331.75 324.53 320.80
275 279.19 361.06 353.69 349.90
300 304.00 389.50 382.07 378.21
control group used at interim analysis above 50% (Fig. 5).
Taking also the recruited sample size into account, it
seems that a time point between 12 and
2
3 of the control
patients is a good choice as a trade-off between match-
ing rate and sample size (Fig. 7). The matching rate lies
between 90.7% and 93.4% for all considered time points.
In all scenarios, the achieved power is around 80% and the
type I error rate around 5% (Figs. 6, 8).
It seems that for small sample sizes in the control group
a later interim analysis could be a good choice and for
large sample sizes an earlier time point, respectively. Using
only 50% of the control patients at the interim analysis
in small trials leads to a low absolute number of patients
which underestimates the matching rate. For large sam-
ple sizes, it is observed that a smaller absolute number of
control patients leads to a good estimate of the matching
rate. The results are shown in the Additional files 1 and 2:
(Figures S1 to S8).
Real data example
The KEEP SIMPLEST trial aimed to compare aspects of
periinterventional management in AIS patients treated
according to a new SOP (standard operating procedure)
with patients having been randomized into the conscious
sedation group of the SIESTA trial [7].
The CS group of the SIESTA trial includes 77 patients
but only 73 were considered in the matching analysis due
to missings in matching variables. The study protocol
intended an interim analysis after 50 patients to esti-
mate the matching rate. The actually recruited number of
treated patients at interim analysis was 51. We applied the
resampling CI method for the recalculation of sample size
using 200 resampling steps. To compare the two meth-
ods here, we additionally conducted the analysis using the
naive method.
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Fig. 5Mean matching rate for different time points of the interim analysis (ncontrol = 150)
Within the matching procedure, four baseline variables
were considered: Age, NIHSS on admission, premorbid
mRS, and the ASPECTS score. The propensity score
was estimated by a logistic regression model. For the
propensity score matching, a caliper width of 0.2 of the
standard deviation of the propensity score was used. The
interim analysis showed the following results:
mrnaiv =0.607
mr =0.461
The extrapolation ofmr = 0.461 resulted in a total sample
size of 161. The KEEP SIMPLEST data set consists of 154
patients with complete data (161 patients were included
in the trial but 7 patients had a missing ASPECTS
score). The matching procedure reached 0.945 matching
rate in the final analysis, hence 69 pairs were found and
analyzed.
The naive method would result in a total sample size
of 122. Using only 122 patients in the treated group
for the second matching procedure would have resulted
in 63 matched pairs and hence a matching rate of
0.863. Thus, in our real data example, the resampling
CI method achieves a 8.2% higher matching rate in the
final analysis.
Fig. 6 Power for different time points of the interim analysis (ncontrol = 150)
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Fig. 7Mean sample size in treated group for different time points of the interim analysis (ncontrol = 150)
Discussion and conclusion
In this article, we propose to include an interim analy-
sis step within a prospective matched case-control trial.
We showed by simulations that the naive method might
severly overestimate the matching rate at the interim
analysis. This leads to a low matching rate at the final
analysis and, therefore, a too low power. The resampling
CI method avoids this overestimation and the recalcula-
tion results in a higher number of treated patients. As a
consequence, a higher matching rate can be achieved at
the final analysis and this is related to a gain in power.
At the same time this approach still leads to a reason-
able sample size and is therefore a very efficient approach.
An increase of the confidence level showed only a small
influence on the sample size in the treatment group and
matching rate at final analysis. The application to a real
data example also showed that the resampling CI method
leads to a very good matching rate in contrast to the
naive approach.
Our proposed approach is a powerful technique to reach
a good matching rate and a high power at the final analy-
sis. The simulation study demonstrates the characteristics
Fig. 8 Type I error for different time points of the interim analysis (ncontrol = 150)
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of the approaches based on a single model including dif-
ferent types of covariates. Even though more complex
models are not evaluated in the simulations, a higher
model complexity is not expected to strongly influence
the performance of the approaches when model conver-
gence is guaranteed. A higher degree of misspecification
of the propensity score model would lead to a lower
matching rate. However, this would be the case for both
methods. A limitation of our approach is the very spe-
cific application area and the relatively high number of
intervention patients to be included. Another limitation
is the fact that the maximal sample size per group is
limited by the number of patients in the control group
which leads to power restrictions. On the other hand,
in case a very large control group exists, for instance
out of a registry, our proposed method might underesti-
mate the true matching rate at interim analysis and one
should consider a 1 : k matching design. As a trade-off
between matching rate, power, and sample size, we rec-
ommend a proportion of 12 to
2
3 of the number of patients
in the control group at the interim analysis. It appears
that it depends more on the absolute number of patients
at the interim analysis than on the relative number of
control patients to get a good estimate for the matching
rate. Giving a recommendation for an absolute number
of patients needed for the interim analysis independent
of the trial size is difficult, because this number would
be limited by the trials with a small sample size. Never-
theless, we provide clear recommendations for situations
that appear typical in clinical trials and therefore help-
ful instructions for clinicial researchers in the planning
stage of a trial.
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